Missouri · Q0138

Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) in Missouri

Missouri Medicare Avg
$0.39
1% below national avg
National Medicare Avg
$0.39
All states combined
Billed Charge (MO)
$5.18
What providers submit
Est. Commercial (MO)
$1.05
National avg: $1.12
Est. Cash / Self-Pay (MO)
$1.80
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

138.7K
Services in MO
40
Providers
N/A
Min Payment
N/A
Max Payment

Missouri Pricing in Context

In Missouri, CPT code Q0138 (Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use)) carries an average Medicare payment of $0.39 — 1% below the national benchmark of $0.39. 40 providers across the state submitted claims for this procedure in 2023, performing 138.7K total services. Individual payments in MO ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Missouri is $5.18, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Missouri sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Temporary Codes procedures, the estimated commercial insurance price in Missouri lands near $1.05, with self-pay cash prices typically around $1.80. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) cost in Missouri?

The average Medicare payment for Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) in Missouri is $0.39, which is 1% below the national average of $0.39. Providers in MO typically bill $5.18 for this procedure.

What does Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) cost with insurance in Missouri?

With commercial insurance in Missouri, Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) costs an estimated $1.05. Without insurance, the estimated cash price is $1.80. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) in Missouri?

40 providers in Missouri billed Medicare for Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) in 2023, performing 138.7K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) cheaper in Missouri than the national average?

Yes — Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (non-Esrd Use) costs 1% below the national average in Missouri. The state average Medicare payment is $0.39 compared to $0.39 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial